# Stem Cells in Rapidly Evolving Active Multiple Sclerosis

> **NCT01606215** · PHASE1,PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 21 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Mesenchymal stem cells
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01606215
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01606215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01606215, "Stem Cells in Rapidly Evolving Active Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01606215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*